EyePoint, Inc. (EYPT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 11:20 AM EDT
Company Participants
Jay Duker – President, CEO & Director
George Elston – Executive VP & CFO
Presentation
Unknown Analyst
Great. First, welcome to Jay Duker and George Elston from EyePoint Pharmaceuticals here at the 47th Annual Goldman Sachs Healthcare Conference. Welcome, gentlemen.
Jay Duker
President, CEO & Director
Thank you very much.
Question-and-Answer Session
Unknown Analyst
For those in the audience and listening who may be newer to the story, can you start at a high-level overview of EyePoint say, core clinical programs that are advancing and key milestones that you have investors.
Jay Duker
President, CEO & Director
Sure. Happy to answer that question. And again, we really appreciate the invitation. So EyePoint is a drug delivery company for the back of the eye. We hope to improve patients’ lives who have serious retinal diseases. Our lead product is called DURAVYU or EYP-1901. It’s a combination of a small molecule tyrosine kinase inhibitor called vorolanib and our proprietary bioerodible delivery system. Vorolanib is a bit unique because it has activity against all the VEGF receptors. Again, it is a receptor-based treatment as well as PDGF.
And we also block the JAK1 receptor, which means we have an anti-inflammatory effect, which does appear to be important in retinal diseases. We are currently in Phase III in the 2 largest retinal indications, wet age-related macular degeneration and diabetic macular edema. The wet AMD trials are called LUGANO and LUCIA. They are traditional non-inferiority trial endpoints. And the first trial LUGANO is on target to read out sometime in August of this year.
The LUCIA trial is about 2 months behind and therefore, will read out approximately 2 months after that. The diabetic macular edema trials are
